Blog

Yakup Ergün: Patients’ interests must always come first in clinical trials

Yakup Ergün/X

Jan 18, 2025, 22:54

Yakup Ergün: Patients’ interests must always come first in clinical trials

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X by Bishal Gyawali, Associate Professor at Queen’s University, adding:

“An excellent letter regarding the design of the ARANOTE trial. I sincerely congratulate the authors. I had also submitted a letter on this topic, but the editors at JCO did not find it compelling.

Fortunately, they accepted another letter on the same subject. Their speed in rejecting my letter was quite impressive, though—submitted it on September 27 and rejected it the very same day. In their rejection, the editors suggested an alternative journal. I wonder why—after all, they published the study, and this is their responsibility.

Why should I send my letter elsewhere?

Well, I’ll leave it to the editorial board’s discretion. Patients’ interests must always come first in clinical trials. Wherever I see otherwise, I will continue to speak up on every platform without hesitation.”

Yakup Ergün-clinical trials

Quoting Bishal Gyawali’s post:

“Please do read our letter to the editor of the Journal of Clinical Oncology with regard to the recent publication of the ARANOTE trial.

Until when shall we put up with inferior control arms?

Congratulations Abhenil Mittal for raising awareness re this important issue.”

“Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial“

Authors: Abhenil Mittal, Geordie Linford and Bishal Gyawali

Yakup Ergün-clinical trials

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.

More posts featuring Yakup Ergün and Bishal Gyawali.